Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States

The Annals of Pharmacotherapy
Quang A LeYamei Wang

Abstract

The US Food and Drug Administration has recently approved abaloparatide (ABL) for treatment of women with postmenopausal osteoporosis (PMO) at high risk of fracture. With increasing health care spending and drug prices, it is important to quantify the value of newly available treatment options for PMO. To determine cost-effectiveness of ABL compared with teriparatide (TPTD) for treatment of women with PMO in the United States. A discrete-event simulation (DES) model was developed to assess cost-effectiveness of ABL from the US health care perspective. The model included three 18-month treatment strategies with either placebo (PBO), TPTD, or ABL, all followed by additional 5-year treatment with alendronate (ALN). High-risk patients were defined as women with PMO ⩾65 years old with a prior vertebral fracture. Baseline clinical event rates, risk reductions, and patient characteristics were based on the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial. Over a 10-year period, the DES model yielded average total discounted per-patient costs of $10 212, $46 783, and $26 837 and quality-adjusted life-years (QALYs) of 6.742, 6.781, and 6.792 for PBO/ALN, TPTD/ALN, and ABL/ALN, respectively. Compared with TPTD/ALN, AB...Continue Reading

References

Mar 8, 1998·PharmacoEconomics·A Briggs, M Sculpher
Apr 26, 2000·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·C M KlotzbuecherM Berger
Jun 14, 2000·The Journal of Clinical Endocrinology and Metabolism·R S RittmasterC J Rosen
Feb 15, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy
Nov 22, 2001·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·A N TostesonJ D Adachi
Oct 9, 2002·Journal of the American Geriatrics Society·Cynthia L LeibsonL Joseph Melton
Oct 16, 2002·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J E BrazierUNKNOWN Committee Of Scientific Advisors International Osteoporosis Foundation
Sep 15, 2004·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·Olof Johnell, John Kanis
Apr 28, 2005·PharmacoEconomics·J Jaime Caro
May 4, 2005·Annals of Internal Medicine·John T SchousboeKristine E Ensrud
Jul 20, 2005·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J LundkvistD Sykes
Aug 2, 2005·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Richard PrinceBruce H Mitlak
Dec 6, 2006·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Russel BurgeAnna Tosteson
Dec 28, 2006·JAMA : the Journal of the American Medical Association·Dennis M BlackUNKNOWN FLEX Research Group
Feb 23, 2008·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·A N A TostesonUNKNOWN National Osteoporosis Foundation Guide Committee
May 8, 2009·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·B AbrahamsenC Cooper
Aug 26, 2009·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·B EttingerL J Melton
Oct 15, 2009·JAMA : the Journal of the American Medical Association·Carmen A BrauerAllison B Rosen
Jul 8, 2010·Journal of Medical Economics·Fredrik BorgströmOsten Ljunggren
Sep 10, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jaime J CaroDenis Getsios
Sep 3, 2011·Journal of the American Geriatrics Society·Annalise N PhamCathleen S Colón-Emeric
Jan 13, 2012·The Journal of Clinical Endocrinology and Metabolism·Roland Baron, Eric Hesse
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Jonathan KarnonJörgen Möller
Dec 12, 2012·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·O StrömJ A Kanis
Apr 29, 2014·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Nicole C WrightBess Dawson-Hughes
Aug 27, 2015·Journal of Managed Care & Specialty Pharmacy·Lung-I ChengBradley S Stolshek
Mar 12, 2016·Expert Review of Pharmacoeconomics & Outcomes Research·J Jaime Caro, Jörgen Möller
Aug 18, 2016·JAMA : the Journal of the American Medical Association·Paul D MillerUNKNOWN ACTIVE Study Investigators
Sep 24, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Pauline M CamachoNelson B Watts
Mar 28, 2017·Journal of Managed Care & Specialty Pharmacy·Jessica WeaverPanagiotis Marvos
May 6, 2017·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Eugene V McCloskeyJohn A Kanis
May 26, 2018·The Journal of Clinical Endocrinology and Metabolism·Henry G BoneKenneth G Saag

❮ Previous
Next ❯

Citations

Mar 12, 2019·Expert Opinion on Pharmacotherapy·D MerlottiL Gennari
Jul 2, 2020·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Isaac Corro RamosMaureen P M H Rutten-van Mölken
Jul 9, 2020·Clinical Interventions in Aging·Jeremy C ThompsonBrett A Freedman
Oct 8, 2020·PharmacoEconomics·Nannan LiMickaël Hiligsmann
Jan 8, 2021·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·E SöreskogM Charokopou

❮ Previous
Next ❯

Software Mentioned

Visual Basic for Applications ( VBA )
ACTIVExtend
PSA
Excel
ACTIVE

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
W Ni, Y Jiang
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
K MoriwakiHideaki E Takahashi
[Rinshō ketsueki] The Japanese journal of clinical hematology
Masao Tomonaga, Isao Kamae
© 2022 Meta ULC. All rights reserved